Shanghai Junshi Biosciences Co., Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SHJBF research report →
Companywww.junshipharma.com
Shanghai Junshi Biosciences Co. , Ltd. , a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China.
- CEO
- Cong Li
- IPO
- 2021
- Employees
- 2,578
- HQ
- Shanghai, CN
Price Chart
Valuation
- Market Cap
- $4.84B
- P/E
- -60.63
- P/S
- 14.60
- P/B
- 6.80
- EV/EBITDA
- -62.62
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 78.56%
- Op Margin
- -30.43%
- Net Margin
- -24.26%
- ROE
- -10.78%
- ROIC
- -6.50%
Growth & Income
- Revenue
- $2.43B · 24.93%
- Net Income
- $-851,825,036 · 33.58%
- EPS
- $-0.84 · 35.38%
- Op Income
- $-909,470,904
- FCF YoY
- 43.09%
Performance & Tape
- 52W High
- $4.23
- 52W Low
- $1.97
- 50D MA
- $3.06
- 200D MA
- $3.22
- Beta
- 0.61
- Avg Volume
- 16
Get TickerSpark's AI analysis on SHJBF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SHJBF Coverage
We haven't published any research on SHJBF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SHJBF Report →